Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for NASDAQ:SHPGY
-0.48 (-0.20%)
Real-time:   10:32AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 238.68 - 242.41
52 week 141.66 - 264.98
Open 239.10
Vol / Avg. 129,164.00/588,925.00
Mkt cap 47.45B
P/E 14.40
Div/yield 0.57/0.29
EPS 16.70
Shares 599.10M
Beta 0.67
Inst. own 8%
Apr 30, 2015
Q1 2015 Shire PLC Earnings Release - 3:00AM EDT - Add to calendar
Apr 28, 2015
Shire PLC Annual Shareholders Meeting - 9:45AM EDT - Add to calendar
Mar 24, 2015
Shire PLC at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 3, 2015
Shire PLC at Cowen Health Care Conference
Feb 12, 2015
Full Year 2014 Shire PLC Earnings Call
Feb 12, 2015
Full Year 2014 Shire PLC Earnings Release
Jan 13, 2015
Shire PLC at JPMorgan Healthcare Conference (Q&A)
Jan 13, 2015
Shire PLC at JPMorgan Healthcare Conference
Jan 11, 2015
Shire PLC to Acquire NPS Pharma as Further Step in Building a Leading Biotech Inc Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 126.05% 54.47%
Operating margin 30.53% 28.20%
EBITD margin - 43.82%
Return on average assets 63.31% 29.88%
Return on average equity 104.78% 46.80%
Employees 5,016 -
CDP Score - 91 B


5 Riverwalk Citywest Business Campus Dublin 24
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Shire Plc is a specialty biopharmaceutical company that focuses on developing and marketing innovative specialty medicines that address unmet patient needs. The Company�s products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute), CINRYZE. The Company focuses its development resources on projects in a number of therapeutic areas, including Neuroscience, Rare Diseases, Ophthalmology, Hematology and GI, and focuses its early development projects on rare diseases.

Officers and directors

F. Ornskov M.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Jeffrey Poulton Interim Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Tatjana May General Counsel, Company Secretary
Age: 47
Bio & Compensation  - Reuters
Susan S Kilsby Non-Executive Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Dominic Blakemore Non-Executive Director
Age: 45
Bio & Compensation  - Reuters
William Burns Non-Executive Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven H. Gillis Ph.D. Non-Executive Independent Director
Age: 50
Bio & Compensation  - Reuters